Mirion Technologies, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with the three months ended March 31, 2023. Mirion supplies radiation detection, measurement, analysis and monitoring products and services through its Medical and Technologies segments. Figures are in U.S. dollars.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $192.6 million | $182.1 million; up 5.8% |
| Gross profit / margin | $87.1 million / 45.2% | $79.1 million / 43.4% |
| Operating loss | $4.9 million | $13.6 million |
| Net loss attributable to Mirion | $25.8 million; $0.13 per share | $41.9 million; $0.22 per share |
| Adjusted EBITDA (non-GAAP) | $39.5 million | $36.6 million |
| Cash from operations | $6.0 million | $(2.7) million |
| Cash and cash equivalents | $120.2 million at March 31 | $128.8 million at December 31, 2023 |
| Third-party debt | $697.3 million gross; $685.4 million net of financing costs and current portion | $698.4 million gross at December 31, 2023 |
Capital expenditures and purchases of badges were $12.8 million, exceeding operating cash flow; investing cash outflow was $12.9 million. Cash, cash equivalents and restricted cash totaled $121.7 million at quarter-end. The $830 million term-loan facility had an 8.36% interest rate; approximately $694.6 million was outstanding, with maturity in October 2028. No revolver borrowings were outstanding; reported availability was approximately $73.6 million after letters of credit. The company said it was in compliance with debt covenants and expects available liquidity to cover the next 12 months.
Material changes and segment performance
- Technologies: Revenue rose to $125.8 million from $115.7 million; segment operating income increased to $12.6 million from $5.5 million. Growth reflected pricing, organic volume, product mix and foreign exchange, partly offset by project delays.
- Medical: Revenue was broadly unchanged at $66.8 million versus $66.4 million; segment operating income rose to $1.4 million from $0.7 million. Pricing, organic growth and the ec2 acquisition were offset in part by delayed NucMed operations during a new ERP implementation and the prior-year inclusion of the Rehab business, sold in April 2023.
- Consolidated operating loss narrowed primarily on higher Technologies results, lower SG&A and amortization. Net loss also benefited from lower net interest expense and a smaller warrant-liability remeasurement loss ($5.7 million versus $13.4 million). These included non-cash fair-value effects.
- Backlog/remaining performance obligations were $840.5 million at March 31, down from $857.1 million at year-end. The company expects to recognize approximately 45% during 2024, 25% in 2025, 12% in 2026 and 10% in 2027, with the remainder thereafter.
Outlook, risks and unusual items
- No quantified full-year revenue or earnings guidance is provided in the filing. Management cites inflation, interest rates, government budget cycles, supply-chain and geopolitical disruption, foreign exchange, execution on fixed-price contracts, and acquisition integration as factors that may affect results.
- Russian-related projects remain subject to sanctions-related delays. Russian project backlog was approximately $153.7 million; Mirion reported $0.7 million in net contract assets and receivables after reserves, alongside $13.9 million of advance-payment guarantees and $14.1 million of performance guarantees.
- A Russian customer asserts delay damages currently stated at $21 million, subject to a $14 million contractual cap, and separately seeks return of $10.2 million paid for a cancelled Finland project. Management disputes the claims and intends to defend them; outcomes remain uncertain.
- On April 18, 2024, Mirion announced redemption of all outstanding public warrants by May 20, 2024. Holders could exercise for cash at $11.50 per warrant or cashlessly for 0.220 share per warrant; unexercised warrants would be redeemed for $0.10 each. The filing reported 18.75 million public warrants and a $42.0 million related liability at quarter-end.
- A vendor software-license lawsuit was settled on March 30, 2024 with no material effect on the quarter’s financial statements. Management reported no material expected impact from other ordinary-course legal proceedings, while noting outcomes cannot be predicted with certainty.
Important facts for investors to verify
- Whether Russian project delays, customer claims and guarantee obligations affect backlog conversion, revenue or cash flows.
- Whether NucMed operations recover following the ERP implementation and whether Medical segment growth improves.
- Progress converting the $840.5 million backlog into revenue and operating cash flow.
- Debt-service sensitivity to interest rates, covenant headroom and continued access to the revolving facility.
- Public-warrant exercise and redemption results, including any resulting share issuance or cash proceeds.
- Adjusted EBITDA is a non-GAAP measure; review the filing’s reconciliation and adjustments alongside GAAP losses and cash flows.